Albireo Historical Income Statement

Summary

ALBODelisted Stock

USD 44.15 0.75 1.67%

Historical analysis of Albireo Pharma income statement accounts such as Cost of Revenue of 1.2 M, Gross Profit of 48.7 M or Interest Expense of 17.3 M can show how well Albireo Pharma performed in making a profits. Evaluating Albireo Pharma income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Albireo Pharma's future profits or losses. Financial Statement Analysis is much more than just reviewing and examining Albireo Pharma latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Albireo Pharma is a good buy for the upcoming year.

Please continue to Trending Equities.

Net Income Gross Profit

About Albireo Income Statement Analysis

Albireo Pharma Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Albireo Pharma shareholders. The income statement also shows Albireo investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Albireo Pharma Income Statement Chart

Albireo Pharma Income Statement is one of the three primary financial statements used for reporting Albireo's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Albireo Pharma revenue and expense. Albireo Pharma Income Statement primarily focuses on the company's revenues and expenses during a particular period.

Albireo Pharma Weighted Average Shares is very stable at the moment as compared to the past year. Albireo Pharma reported last year Weighted Average Shares of 22.1 Million. As of 20th of March 2023, Weighted Average Shares Diluted is likely to grow to about 23.8 M, while Consolidated Income is likely to drop (33 M).

Earning Before Interest and Taxes EBIT Net Income Revenues

Earning Before Interest and Taxes EBIT

Earnings Before Interest and Tax is calculated by adding Income Tax Expense and Interest Expense back to Net Income.

Net Income

Net income is one of the most important fundamental items in finance. It plays a large role in Albireo Pharma financial statement analysis. It represents the amount of money remaining after all of Albireo Pharma operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. The portion of profit or loss for the period; net of income taxes; which is attributable to the parent after the deduction of Net Income Available to Non-controlling Interests from Consolidated Income; and before the deduction of Preferred Dividends.

Revenues

Revenues refers to the total amount of money received by Albireo Pharma for goods sold or services provided during a certain time period. It also includes all of Albireo Pharma sales as well as any other increase in Albireo Pharma equity.Revenues are reported on Albireo Pharma income statement and calculated before any expenses are subtracted. The amount of Revenue recognised from goods sold; services rendered; insurance premiums; or other activities that constitute an earning process. Interest income for financial institutions is reported net of interest expense and provision for credit losses.

Most accounts from Albireo Pharma's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Albireo Pharma current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Please continue to Trending Equities.Albireo Pharma Weighted Average Shares is very stable at the moment as compared to the past year. Albireo Pharma reported last year Weighted Average Shares of 22.1 Million. As of 20th of March 2023, Weighted Average Shares Diluted is likely to grow to about 23.8 M, while Consolidated Income is likely to drop (33 M).

	2020	2021	2022	2023 (projected)
Revenues USD	8.31 M	40.58 M	46.67 M	50.35 M
Revenues	8.31 M	40.58 M	46.67 M	50.35 M

Revenues USD Revenues

Albireo Pharma income statement Correlations

	Direct Expenses	Consolidated Income	Cost of Revenue	Gross Profit	Interest Expense	Net Income	Net Income Common Stock	Operating Expenses	Operating Income	Revenues	Research and Development Expense	Weighted Average Shares	Weighted Average Shares Diluted	Income Tax Expense
Direct Expenses		0.0	1.0	-0.83	-0.76	0.0	0.0	-0.78	0.62	-0.83	-0.72	-0.69	-0.69	0.16
Consolidated Income	0.0		0.0	-0.09	-0.45	1.0	1.0	-0.39	0.55	-0.09	-0.54	-0.55	-0.55	0.23
Cost of Revenue	1.0	0.0		-0.83	-0.76	0.0	0.0	-0.78	0.62	-0.83	-0.72	-0.69	-0.69	0.16
Gross Profit	-0.83	-0.09	-0.83		0.92	-0.09	-0.09	0.94	-0.85	1.0	0.87	0.84	0.84	-0.32
Interest Expense	-0.76	-0.45	-0.76	0.92		-0.45	-0.45	0.99	-0.96	0.92	0.99	0.93	0.93	-0.38
Net Income	0.0	1.0	0.0	-0.09	-0.45		1.0	-0.39	0.55	-0.09	-0.54	-0.55	-0.55	0.23
Net Income Common Stock	0.0	1.0	0.0	-0.09	-0.45	1.0		-0.39	0.55	-0.09	-0.54	-0.55	-0.55	0.23
Operating Expenses	-0.78	-0.39	-0.78	0.94	0.99	-0.39	-0.39		-0.97	0.94	0.98	0.95	0.95	-0.29
Operating Income	0.62	0.55	0.62	-0.85	-0.96	0.55	0.55	-0.97		-0.85	-0.99	-0.95	-0.95	0.3
Revenues	-0.83	-0.09	-0.83	1.0	0.92	-0.09	-0.09	0.94	-0.85		0.87	0.84	0.84	-0.31
Research and Development Expense	-0.72	-0.54	-0.72	0.87	0.99	-0.54	-0.54	0.98	-0.99	0.87		0.96	0.96	-0.33
Weighted Average Shares	-0.69	-0.55	-0.69	0.84	0.93	-0.55	-0.55	0.95	-0.95	0.84	0.96		1.0	-0.16
Weighted Average Shares Diluted	-0.69	-0.55	-0.69	0.84	0.93	-0.55	-0.55	0.95	-0.95	0.84	0.96	1.0		-0.16
Income Tax Expense	0.16	0.23	0.16	-0.32	-0.38	0.23	0.23	-0.29	0.3	-0.31	-0.33	-0.16	-0.16

Click cells to compare fundamentals

Albireo Pharma Account Relationship Matchups

Albireo Pharma income statement Accounts

	2018	2019	2020	2021	2022	2023 (projected)
Consolidated Income	(46.11 M)	(62.72 M)	(107.63 M)	(34.03 M)	(30.63 M)	(33.04 M)
Earning Before Interest and Taxes EBIT	(41.25 M)	(57.42 M)	(96.27 M)	(20.1 M)	(18.09 M)	(19.52 M)
Earning Before Interest and Taxes USD	(41.25 M)	(57.42 M)	(96.27 M)	(20.1 M)	(18.09 M)	(19.52 M)
Gross Profit	12.74 M	9.64 M	8.31 M	39.22 M	45.11 M	48.67 M
Interest Expense	4.84 M	5.3 M	11.36 M	13.93 M	16.02 M	17.29 M
Net Income	(46.11 M)	(62.72 M)	(107.63 M)	(34.03 M)	(30.63 M)	(33.04 M)
Net Income Common Stock	(46.11 M)	(62.72 M)	(107.63 M)	(34.03 M)	(30.63 M)	(33.04 M)
Net Income Common Stock USD	(46.11 M)	(62.72 M)	(107.63 M)	(34.03 M)	(30.63 M)	(33.04 M)
Operating Expenses	50.63 M	70.75 M	104.58 M	162.71 M	187.11 M	201.89 M
Operating Income	(37.89 M)	(61.11 M)	(96.27 M)	(123.48 M)	(111.14 M)	(114.06 M)
Revenues	12.74 M	9.64 M	8.31 M	40.58 M	46.67 M	50.35 M
Revenues USD	12.74 M	9.64 M	8.31 M	40.58 M	46.67 M	50.35 M
Research and Development Expense	31.73 M	45.58 M	76.78 M	82.52 M	94.9 M	102.39 M
Selling General and Administrative Expense	18.06 M	22.96 M	42.45 M	69.57 M	80 M	86.32 M
Weighted Average Shares	11.7 M	12.44 M	15.98 M	19.22 M	22.1 M	23.85 M
Weighted Average Shares Diluted	11.7 M	12.44 M	15.98 M	19.22 M	22.1 M	23.85 M

Be your own money manager

Our tools can tell you how much better you can do entering a position in Albireo Pharma without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Portfolio File Import Now

Portfolio File Import

Quickly import all of your third-party portfolios from your local drive in csv format

All Next

Launch Module

Pair Trading with Albireo Pharma

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Albireo Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Albireo Pharma will appreciate offsetting losses from the drop in the long position's value.

Moving against Albireo Pharma

-	0.85	ABIO	ARCA Biopharma	Fiscal Quarter End 31st of March 2023	Pair Corr
-	0.74	ACER	Acer Therapeutics	Financial Report 15th of May 2023	Pair Corr
-	0.55	AADI	Aadi Bioscience	Financial Report 11th of May 2023	Pair Corr
-	0.53	ACGN	Aceragen	Symbol Change	Pair Corr

The ability to find closely correlated positions to Albireo Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Albireo Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Albireo Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Albireo Pharma to buy it.

The correlation of Albireo Pharma is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Albireo Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Albireo Pharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Albireo Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Please continue to Trending Equities. Note that the Albireo Pharma information on this page should be used as a complementary analysis to other Albireo Pharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Money Managers module to screen money managers from public funds and ETFs managed around the world.

Other Consideration for investing in Albireo Stock

If you are still planning to invest in Albireo Pharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Albireo Pharma's history and understand the potential risks before investing.

	Fund Screener Find actively-traded funds from around the world traded on over 30 global exchanges
	Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
	Analyst Recommendations Analyst recommendations and target price estimates broken down by several categories
	Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities
	Commodity Channel Index Use Commodity Channel Index to analyze current equity momentum
	Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
	Watchlist Optimization Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
	Share Portfolio Track or share privately all of your investments from the convenience of any device
	Money Managers Screen money managers from public funds and ETFs managed around the world
	Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges
	Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
	Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2023 Macroaxis LLC

Albireo Historical Income Statement

About Albireo Income Statement Analysis

Albireo Pharma Income Statement Chart

Earning Before Interest and Taxes EBIT

Net Income

Revenues

Albireo Pharma income statement Correlations

Albireo Pharma Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Albireo Pharma income statement Accounts

Be your own money manager

Did you try this?

Run Portfolio File Import Now

Portfolio File Import

Pair Trading with Albireo Pharma

Moving against Albireo Pharma

Other Consideration for investing in Albireo Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cost of Revenue	+ 1.0	Direct Expenses
Net Income	+ 1.0	Consolidated Income
Net Income Common Stock	+ 1.0	Consolidated Income
Revenues	+ 1.0	Gross Profit
Net Income Common Stock	+ 1.0	Net Income
Weighted Average Shares Diluted	+ 1.0	Weighted Average Shares

Research and Development Expense	- 0.99	Operating Income
Operating Income	- 0.97	Operating Expenses
Operating Income	- 0.96	Interest Expense
Weighted Average Shares Diluted	- 0.95	Operating Income
Weighted Average Shares	- 0.95	Operating Income
Revenues	- 0.85	Operating Income